ACAD Key Statistics, Chart & Performance
The current stock price of ACAD is 25.99 USD. In the past month the price decreased by -3.49%. In the past year, price increased by 47.92%.
ACAD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ACAD. When comparing the yearly performance of all stocks, ACAD is one of the better performing stocks in the market, outperforming 89.22% of all stocks.
ACAD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ACAD. While ACAD has a great health rating, its profitability is only average at the moment.
ACAD Financial Highlights
Over the last trailing twelve months ACAD reported a non-GAAP Earnings per Share(EPS) of 0.67. The EPS decreased by -14.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.94% | ||
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| Debt/Equity | 0 |
ACAD Forecast & Estimates
26 analysts have analysed ACAD and the average price target is 30.87 USD. This implies a price increase of 18.77% is expected in the next year compared to the current price of 25.99.
For the next year, analysts expect an EPS growth of 71.6% and a revenue growth 11.07% for ACAD
ACAD Ownership
ACAD Latest News, Press Relases and Analysis
ACAD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About ACAD
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Company Info
ACADIA PHARMACEUTICALS INC
12830 El Camino Real, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Stephen R. Davis
Employees: 653
Phone: 18585582871
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What does ACAD do?
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
What is the stock price of ACADIA PHARMACEUTICALS INC today?
The current stock price of ACAD is 25.99 USD. The price decreased by -2.04% in the last trading session.
What is the dividend status of ACADIA PHARMACEUTICALS INC?
ACAD does not pay a dividend.
What is the ChartMill rating of ACADIA PHARMACEUTICALS INC stock?
ACAD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does ACADIA PHARMACEUTICALS INC belong to?
ACADIA PHARMACEUTICALS INC (ACAD) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for ACAD stock?
The Revenue of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 11.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ACAD stock?
ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of 4.40B USD. This makes ACAD a Mid Cap stock.